The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma

William J. Anderson, Philip M. Short, Peter A. Williamson, Arvind Manoharan, Brian J. Lipworth (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    The murine asthma model shows that switching off airway ß2 receptors with an inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing activity. We have assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, added to low-dose inhaled corticosteroid (ICS) compared with higher dose ICS. A randomized double-blind placebo-controlled cross-over trial in mild-to-moderate persistent asthmatic patients was performed. After a run-in (2 weeks) on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) at 100 µg/day (HFA-BDP100), patients received randomized treatments (4 weeks) with propranolol at 80 mg/day plus HFA-BDP at 100 µg/day compared with placebo plus HFA-BDP at 400 µg/day (HFA-BDP400). Propranolol was up-titrated to 80 mg/day over the initial 2 weeks. Tiotropium was co-administered until 5 days before each histamine challenge (the primary outcome). Sixteen patients completed the study [mean age, 38 years; forced expiratory volume in 1 s (FEV1), 86.4%; histamine provocative concentration causing a 20% fall in FEV1 (PC20), 1.39 mg/ml; ICS dose, 406 µg/day]. Histamine PC20 was unchanged by adding propranolol to HFA-BDP100 compared with baseline (HFA-BDP100) {0.17 doubling dilution (dd) difference [95% confidence interval (CI): -0.58 to 0.92]}, but there was a significant improvement with HFA-BDP400 compared with both baseline [1.05 dd (95% CI: 0.43-1.66); P=0.02], and propranolol+HFA-BDP100 [0.88 dd (95% CI: 0.45-1.30); P=0.006]. Significant improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms compared with propranolol+HFA-BDP100. Salbutamol recovery post-challenge was partially blunted by propranolol (median prolongation 5 min; P=0.002). Domiciliary evening FEV1 also fell with propranolol+HFA-BDP100 [mean reduction from baseline 0.22 litres (95% CI: 0.10-0.34); P=0.012], whereas Asthma Control Questionnaire remained unchanged. In conclusion, the inverse agonist propranolol produced no improvements when given with low-dose ICS, whereas further significant improvements in airway hyper-responsiveness and inflammation were demonstrated with higher dose ICS. Thus, propranolol does not confer corticosteroid-sparing activity in persistent asthma.
    Original languageEnglish
    Pages (from-to)635-643
    Number of pages9
    JournalClinical Science
    Volume127
    Issue number11
    DOIs
    Publication statusPublished - Dec 2014

    Fingerprint

    Propranolol
    Adrenal Cortex Hormones
    Asthma
    HFA 134a
    Beclomethasone
    Forced Expiratory Volume
    Confidence Intervals
    Histamine
    Respiratory Hypersensitivity
    Placebos
    Albuterol
    Eosinophils
    Cross-Over Studies
    Nitric Oxide
    Anti-Inflammatory Agents
    Quality of Life
    Inflammation
    Serum

    Keywords

    • Adult
    • Asthma
    • Beclomethasone
    • Bronchial Provocation Tests
    • Creatinine
    • DNA-Binding Proteins
    • Double-Blind Method
    • Eosinophilia
    • Female
    • Humans
    • Hydrocarbons, Fluorinated
    • Hydrocortisone
    • Male
    • Nuclear Proteins
    • Potassium
    • Propranolol

    Cite this

    Anderson, William J. ; Short, Philip M. ; Williamson, Peter A. ; Manoharan, Arvind ; Lipworth, Brian J. / The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma. In: Clinical Science. 2014 ; Vol. 127, No. 11. pp. 635-643.
    @article{70c2ed3168e140ab80baed8786c33a7a,
    title = "The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma",
    abstract = "The murine asthma model shows that switching off airway {\ss}2 receptors with an inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing activity. We have assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, added to low-dose inhaled corticosteroid (ICS) compared with higher dose ICS. A randomized double-blind placebo-controlled cross-over trial in mild-to-moderate persistent asthmatic patients was performed. After a run-in (2 weeks) on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) at 100 µg/day (HFA-BDP100), patients received randomized treatments (4 weeks) with propranolol at 80 mg/day plus HFA-BDP at 100 µg/day compared with placebo plus HFA-BDP at 400 µg/day (HFA-BDP400). Propranolol was up-titrated to 80 mg/day over the initial 2 weeks. Tiotropium was co-administered until 5 days before each histamine challenge (the primary outcome). Sixteen patients completed the study [mean age, 38 years; forced expiratory volume in 1 s (FEV1), 86.4{\%}; histamine provocative concentration causing a 20{\%} fall in FEV1 (PC20), 1.39 mg/ml; ICS dose, 406 µg/day]. Histamine PC20 was unchanged by adding propranolol to HFA-BDP100 compared with baseline (HFA-BDP100) {0.17 doubling dilution (dd) difference [95{\%} confidence interval (CI): -0.58 to 0.92]}, but there was a significant improvement with HFA-BDP400 compared with both baseline [1.05 dd (95{\%} CI: 0.43-1.66); P=0.02], and propranolol+HFA-BDP100 [0.88 dd (95{\%} CI: 0.45-1.30); P=0.006]. Significant improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms compared with propranolol+HFA-BDP100. Salbutamol recovery post-challenge was partially blunted by propranolol (median prolongation 5 min; P=0.002). Domiciliary evening FEV1 also fell with propranolol+HFA-BDP100 [mean reduction from baseline 0.22 litres (95{\%} CI: 0.10-0.34); P=0.012], whereas Asthma Control Questionnaire remained unchanged. In conclusion, the inverse agonist propranolol produced no improvements when given with low-dose ICS, whereas further significant improvements in airway hyper-responsiveness and inflammation were demonstrated with higher dose ICS. Thus, propranolol does not confer corticosteroid-sparing activity in persistent asthma.",
    keywords = "Adult, Asthma, Beclomethasone, Bronchial Provocation Tests, Creatinine, DNA-Binding Proteins, Double-Blind Method, Eosinophilia, Female, Humans, Hydrocarbons, Fluorinated, Hydrocortisone, Male, Nuclear Proteins, Potassium, Propranolol",
    author = "Anderson, {William J.} and Short, {Philip M.} and Williamson, {Peter A.} and Arvind Manoharan and Lipworth, {Brian J.}",
    year = "2014",
    month = "12",
    doi = "10.1042/CS20140249",
    language = "English",
    volume = "127",
    pages = "635--643",
    journal = "Clinical Science",
    issn = "0143-5221",
    publisher = "Portland Press",
    number = "11",

    }

    The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma. / Anderson, William J.; Short, Philip M.; Williamson, Peter A.; Manoharan, Arvind; Lipworth, Brian J. (Lead / Corresponding author).

    In: Clinical Science, Vol. 127, No. 11, 12.2014, p. 635-643.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma

    AU - Anderson, William J.

    AU - Short, Philip M.

    AU - Williamson, Peter A.

    AU - Manoharan, Arvind

    AU - Lipworth, Brian J.

    PY - 2014/12

    Y1 - 2014/12

    N2 - The murine asthma model shows that switching off airway ß2 receptors with an inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing activity. We have assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, added to low-dose inhaled corticosteroid (ICS) compared with higher dose ICS. A randomized double-blind placebo-controlled cross-over trial in mild-to-moderate persistent asthmatic patients was performed. After a run-in (2 weeks) on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) at 100 µg/day (HFA-BDP100), patients received randomized treatments (4 weeks) with propranolol at 80 mg/day plus HFA-BDP at 100 µg/day compared with placebo plus HFA-BDP at 400 µg/day (HFA-BDP400). Propranolol was up-titrated to 80 mg/day over the initial 2 weeks. Tiotropium was co-administered until 5 days before each histamine challenge (the primary outcome). Sixteen patients completed the study [mean age, 38 years; forced expiratory volume in 1 s (FEV1), 86.4%; histamine provocative concentration causing a 20% fall in FEV1 (PC20), 1.39 mg/ml; ICS dose, 406 µg/day]. Histamine PC20 was unchanged by adding propranolol to HFA-BDP100 compared with baseline (HFA-BDP100) {0.17 doubling dilution (dd) difference [95% confidence interval (CI): -0.58 to 0.92]}, but there was a significant improvement with HFA-BDP400 compared with both baseline [1.05 dd (95% CI: 0.43-1.66); P=0.02], and propranolol+HFA-BDP100 [0.88 dd (95% CI: 0.45-1.30); P=0.006]. Significant improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms compared with propranolol+HFA-BDP100. Salbutamol recovery post-challenge was partially blunted by propranolol (median prolongation 5 min; P=0.002). Domiciliary evening FEV1 also fell with propranolol+HFA-BDP100 [mean reduction from baseline 0.22 litres (95% CI: 0.10-0.34); P=0.012], whereas Asthma Control Questionnaire remained unchanged. In conclusion, the inverse agonist propranolol produced no improvements when given with low-dose ICS, whereas further significant improvements in airway hyper-responsiveness and inflammation were demonstrated with higher dose ICS. Thus, propranolol does not confer corticosteroid-sparing activity in persistent asthma.

    AB - The murine asthma model shows that switching off airway ß2 receptors with an inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing activity. We have assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, added to low-dose inhaled corticosteroid (ICS) compared with higher dose ICS. A randomized double-blind placebo-controlled cross-over trial in mild-to-moderate persistent asthmatic patients was performed. After a run-in (2 weeks) on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) at 100 µg/day (HFA-BDP100), patients received randomized treatments (4 weeks) with propranolol at 80 mg/day plus HFA-BDP at 100 µg/day compared with placebo plus HFA-BDP at 400 µg/day (HFA-BDP400). Propranolol was up-titrated to 80 mg/day over the initial 2 weeks. Tiotropium was co-administered until 5 days before each histamine challenge (the primary outcome). Sixteen patients completed the study [mean age, 38 years; forced expiratory volume in 1 s (FEV1), 86.4%; histamine provocative concentration causing a 20% fall in FEV1 (PC20), 1.39 mg/ml; ICS dose, 406 µg/day]. Histamine PC20 was unchanged by adding propranolol to HFA-BDP100 compared with baseline (HFA-BDP100) {0.17 doubling dilution (dd) difference [95% confidence interval (CI): -0.58 to 0.92]}, but there was a significant improvement with HFA-BDP400 compared with both baseline [1.05 dd (95% CI: 0.43-1.66); P=0.02], and propranolol+HFA-BDP100 [0.88 dd (95% CI: 0.45-1.30); P=0.006]. Significant improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms compared with propranolol+HFA-BDP100. Salbutamol recovery post-challenge was partially blunted by propranolol (median prolongation 5 min; P=0.002). Domiciliary evening FEV1 also fell with propranolol+HFA-BDP100 [mean reduction from baseline 0.22 litres (95% CI: 0.10-0.34); P=0.012], whereas Asthma Control Questionnaire remained unchanged. In conclusion, the inverse agonist propranolol produced no improvements when given with low-dose ICS, whereas further significant improvements in airway hyper-responsiveness and inflammation were demonstrated with higher dose ICS. Thus, propranolol does not confer corticosteroid-sparing activity in persistent asthma.

    KW - Adult

    KW - Asthma

    KW - Beclomethasone

    KW - Bronchial Provocation Tests

    KW - Creatinine

    KW - DNA-Binding Proteins

    KW - Double-Blind Method

    KW - Eosinophilia

    KW - Female

    KW - Humans

    KW - Hydrocarbons, Fluorinated

    KW - Hydrocortisone

    KW - Male

    KW - Nuclear Proteins

    KW - Potassium

    KW - Propranolol

    U2 - 10.1042/CS20140249

    DO - 10.1042/CS20140249

    M3 - Article

    VL - 127

    SP - 635

    EP - 643

    JO - Clinical Science

    JF - Clinical Science

    SN - 0143-5221

    IS - 11

    ER -